The aftershocks of COVID-19 can still be felt, and certain countries are still struggling with its after-effects. The significant increase in external funding from private and government organizations had massively propelled the development of mRNA-based COVID-19 vaccines to meet the growing demand.
Messenger ribonucleic acid (mRNA)-based vaccine is a new type of vaccine that protects individuals from life-threatening infectious diseases such as COVID-19. The mRNA-based vaccines are one of the new classes of vaccine that facilitate the cells in the body to make specific proteins for triggering an immune response, further producing antibodies against a specific disease.
mRNA-based therapeutics have the potential to regulate protein expressions to enhance clinical outcomes, thereby making them suitable for the treatment of complex genetic disorders.
In order to battle the COVID-19 pandemic, several pharmaceutical companies are developing vaccines. Kathrin Jansen, head of Pfizer’s vaccine research and development, recently stated that mRNA technology had been used to develop the Pfizer-BioNTech COVID-19 vaccine. She highlighted that the flexibility of mRNA technology helps in pivoting and adjusting the flu vaccine, thus enabling in matching the more dominant strain easily.
The field of mRNA-based vaccines and therapeutics for non-COVID-19 application is also expanding due to the advancements being made in the clinical trials of new product candidates for various life-threatening diseases such as oncology and rare diseases.
The mRNA-based vaccines and therapeutics for non-COVID-19 applications are expected to offer massive opportunities in the forthcoming years due to increasing research and development expenditure by the company, increasing awareness about the potential of mRNA technology, and growing prominence of targeted therapeutics, among others.
In a recently published market intelligence report by BIS Research, it has been highlighted that the Global mRNA Vaccines and Therapeutics Market is expected to grow at a CAGR of 95.49% during the forecast period 2026-2031 for the non-COVID-19 vaccines.
The growth of the global mRNA vaccines and therapeutics market is driven by factors such as the increasing number of cases of COVID-19 globally, a favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines. However, the impact of these factors is going to be high only in the short term, that is, till 2025.
The high rate of infection has resulted in a pandemic, which has emerged as one of the massive humanitarian challenges in recent times. With a steep rise in the number of COVID-19 patients, there exists a strong requirement of effective and efficacious vaccines by refueling vaccine innovation.
Although there has been a wide array of COVID-19 vaccines in places, such as inactivated vaccines, live-attenuated vaccines, and viral vector vaccines, mRNA-based vaccines are considered to be the most promising on account of their advantages. The mRNA-based COVID-19 vaccines increase protein translation, innate modulation and offer adaptive immunogenicity to the patients suffering from COVID-19.
The mRNA-based vaccines and therapeutics for non-COVID-19 applications are currently under clinical development. The successful launch of these treatment modalities after obtaining regulatory approval is expected to offer transformative care to patients suffering from diseases such as cancer and rare diseases.
